Director/PDMR Shareholding

RNS Number : 7704X
GlaxoSmithKline PLC
20 February 2012
 



Notification of Transactions of

Directors and Persons Discharging Managerial Responsibility

 

Vesting of conditional options granted under GlaxoSmithKline Share Option Plan

 

This notification sets out information relating to the vesting of share options granted in 2009 under the GlaxoSmithKline Share Option Plan (SOP).

 

On 17 February 2009, share options were granted under the SOP to Executive Directors and Persons Discharging Managerial Responsibility (PDMR) at an option price of £11.77, or US $33.42 in the case of an American Depositary Share (ADS). The exercise of the options was subject to an EPS performance condition.

 

The performance period for 50% of the options granted in 2009 to Executive Directors and PDMRs commenced on 1 January 2009 and ended on 31 December 2011. The remaining 50% of the option is subject to meeting a performance condition over a four-year performance period which commenced on 1 January 2009 and will end on 31 December 2012.

 

The Company did not achieve the EPS performance condition at the end of the three-year performance period to 31 December 2011 and therefore the Remuneration Committee has confirmed the options conditionally granted to the participants listed below all lapsed on 17 February 2012. The remaining 2009 options subject to the four-year performance period ending 31 December 2012 will be assessed in February 2013 and are also set out below.

 

 

 

 

Number of options over Shares/ADSs which lapsed

 

 

Remaining options over Shares/ADSs subject to a four-year performance period ending 31 December 2012

 

Ordinary Shares

ADSs

Ordinary Shares

ADSs

Dr M Slaoui*


79,375


79,375

Mr S M Bicknell

25,250


25,250


Mr J M Clarke

88,750


88,750


Ms D Connelly


88,750


88,750

Mr M Dunoyer

46,250


46,250


Mr E J Gray

57,500


57,500


Mr A Hussain

88,750


88,750


Mr W Louv


28,750


28,750

Mr D Pulman


44,375


44,375

Mr D S Redfern

35,000


35,000


Mr J R Stephenne

57,500


57,500


Ms C Thomas

46,250


46,250


Mr D Troy


44,375


44,375

* denotes an Executive Director

 

Options were also granted in 2009 to senior executives who have since become PDMRs. Those options were not subject to performance conditions and become exercisable three years after the date of grant.  The Remuneration Committee has confirmed that all of those options became exercisable (with an option price of £11.77) on 17 February 2012.

 


 

Number of options over Shares/ADSs exercisable

 

Ordinary Shares

Mr P Thomson

6910

Dr P Vallance

94,320

Mrs V Whyte

6910

 

 

The Company, Executive Directors and PDMRs were advised of these transactions on 20 February 2012.

 

This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

 

V A Whyte

Company Secretary

 

20 February 2012

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSVBLFLLLFLBBE

Companies

GSK (GSK)
UK 100

Latest directors dealings